CRISPR Therapeutics and ViaCyte, Inc. announced the first patient has been dosed in the Phase I clinical trial of VCTX210 for the treatment of T1D.
[ViaCyte, Inc.]
Sorry, but the selected Zotpress account can't be found.
Sorry, but the selected Zotpress account can't be found.